DataString Consulting Company Logo
DataString Consulting Company Logo
Iopamidol Market
Home»Recent Reports»Iopamidol Market

Iopamidol Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1806047, Published - April 2025

Segmented in Formulation (Intravenous, Intra-arterial, Intrathecal, Intracavitary), Iodine concentration (300 mg, 370 mg, 200 mg, 250 mg), Imaging Modality, End User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Iopamidol Market Outlook

The market, for Iopamidol was estimated at $636.2 million in 2024; and it is anticipated to increase to $867.3 million by 2030 with projections indicating a growth to around $1.1 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 5.3% over the forecast period. The remarkable expansion of the Iopamidol market is primarily driven by an increase in diagnostic imaging procedures worldwide. The growing prevalence of chronic diseases, including heart diseases and stroke, which require imaging contrast agents, plays a significant part in Iopamidols continuing relevance. Additionally, advancements in contrast media technologies coupled with higher accessibility to healthcare facilities are reinforcing the global Iopamidol market, making it an integral part of the diagnostic imaging sector. Furthermore, increased healthcare spending in emerging economies coupled with improved awareness about the benefits of early disease detection promotes sustained usage of Iopamidol and accentuates its market prominence.


Iopamidol is a nonionic, water-soluble radiographic contrast media, developed to enhance visualization during angiographic procedures and computed tomography (CT) scans. It has gained popularity due to its superior patient tolerance, low toxicity, and high stability. Primarily used in cardiovascular imaging and neurological scans, Iopamidol provides excellent opacification and delineation of vascular structures, contributing to better patient outcomes.


Market Size Forecast & Key Insights

2019
$636M2024
2029
$1.1B2034

Absolute Growth Opportunity = $430M

The Iopamidol market is projected to grow from $636.2 million in 2024 to $1.07 billion in 2034. This represents a CAGR of 5.3%, reflecting rising demand across Diagnostic Imaging, Myelography and Cerebral Angiography.

The Iopamidol market is set to add $430 million between 2024 and 2034, with manufacturer targeting 370 mg & 200 mg Iodine concentration projected to gain a larger market share.

With Surging demand for diagnostic imaging, and Expansion of the geriatric population, Iopamidol market to expand 68% between 2024 and 2034.

Opportunities in the Iopamidol Market

Harnessing Radiology Advancements

Cutting-edge imaging procedures present an underutilized avenue for Iopamidol. As an X-ray contrast agent, Iopamidols use in radiology can witness exponential growth with rising technological advancements and modern imaging procedures in the healthcare sector. Key strategic collaborations with technology developers can tap into this potential.

Expanding Iopamidols Global Reach and Responding to Evolving Patient Needs

Despite its extensive use in developed economies, Iopamidols penetration in emerging economies remains notably low. Strategic regional expansion into these markets with high potential, such as India and Brazil, could prove highly beneficial. The upsurge in lifestyle diseases in these countries, coupled with improving healthcare infrastructure, mark a significant growth for Iopamidol.

With growing concerns over patient safety and comfort, there is an increasing demand for non-ionic, isotonic contrast agents like Iopamidol. By aligning product development and marketing outreach initiatives to emphasize Iopamidols safety profile, companies can effectively cater to this evolving patient need and carve out a distinctive niche in the competitive market.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe, the consumption of Iopamidol is on an upward trajectory, prompted by the escalating demand for non-invasive diagnostic procedures. The countries contributing significantly to the markets expansion include Germany, France, and the United Kingdom, propelled by their strong healthcare infrastructure and policies advocating timely medical diagnosis. There is intense competition among major players such as Guerbet and Bayer AG, focusing on innovative product development and marketing strategies. Driving factors for the markets growth include the increasing incidence of chronic diseases like cancer, liver disorders, and heart diseases, necessitating diagnostic imaging, a potent demand for Iopamidol.

North America Outlook

The North American region, particularly the United States, constitutes a significant portion of the global Iopamidol market, driven by the high incidence of heart diseases and cancers requiring diagnostic procedures. This region invests heavily in medical imaging technology and radiology, where Iopamidol, primarily used as an X-ray contrast agent, plays a vital role. There is intense competition among key players such as Bracco Imaging and Jubilant Pharma who are constantly striving to increase their product portfolio and improve their formulations. The major drivers include advanced healthcare infrastructure, increased healthcare expenditure, and an aging population requiring regular diagnostics. This affirms the regions leading position in the Iopamidol market and suggests promising growth prospects.

North America Outlook

The North American region, particularly the United States, constitutes a significant portion of the global Iopamidol market, driven by the high incidence of heart diseases and cancers requiring diagnostic procedures. This region invests heavily in medical imaging technology and radiology, where Iopamidol, primarily used as an X-ray contrast agent, plays a vital role. There is intense competition among key players such as Bracco Imaging and Jubilant Pharma who are constantly striving to increase their product portfolio and improve their formulations. The major drivers include advanced healthcare infrastructure, increased healthcare expenditure, and an aging population requiring regular diagnostics. This affirms the regions leading position in the Iopamidol market and suggests promising growth prospects.

Europe Outlook

In Europe, the consumption of Iopamidol is on an upward trajectory, prompted by the escalating demand for non-invasive diagnostic procedures. The countries contributing significantly to the markets expansion include Germany, France, and the United Kingdom, propelled by their strong healthcare infrastructure and policies advocating timely medical diagnosis. There is intense competition among major players such as Guerbet and Bayer AG, focusing on innovative product development and marketing strategies. Driving factors for the markets growth include the increasing incidence of chronic diseases like cancer, liver disorders, and heart diseases, necessitating diagnostic imaging, a potent demand for Iopamidol.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, France, Japan, China are expected to grow at 3.4% to 5.1% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 6.1% to 7.3% CAGR

Market Analysis Chart

The market environment surrounding Iopamidol, a radiopaque contrast agent, is marked by a set of distinct drivers and restraints. Understanding these underlying factors is crucial in predicting the products future trajectory. One significant driver for Iopamidols growing demand stems from its widespread application in diagnostic imaging procedures. Technological advancements in imaging modalities, particularly in computed tomography and cardiovascular angiography, are creating new opportunities for this contrast agent.

Recent Developments and Technological Advancement

December 2024

Reformulation Initiative - Healthcare leader, Bayer AG, announced the successful reformulation of Iopamidol, enhancing its efficacy and reducing potential side effects

October 2024

New Market Entry - Global pharmaceutical firm, Johnson & Johnson, entered the Iopamidol market deploying novel manufacturing processes aimed at reducing production costs and increasing volume

August 2024

Orthopedic Application Advance - Novartis AG significantly expanded their orthopedic applications of Iopamidol, following successful clinical trials demonstrating improved patient comfort and imaging clarity.

Iopamidol, an integral compound in the modern healthcare industry, predominantly employed as a contrast agent for radiographic imaging, has experienced significant market advances in recent times. These trends stem from increased global emphasis on precision diagnostics and healthcare concerns, necessitating more comprehensive and detailed imaging techniques. Enhancements in Iopamidol manufacturing technology present a substantial development that merits attention.

Impact of Industry Transitions on the Iopamidol Market

As a core segment of the Other Healthcare industry, the Iopamidol market develops in line with broader industry shifts. Over recent years, transitions such as The Emergence of Generic Iopamidol and Technological Advancements in Imaging Procedures have redefined priorities across the Other Healthcare sector, influencing how the Iopamidol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

The Emergence of Generic Iopamidol:

Iopamidol, an iodinecontaining nonionic radiopaque contrast medium, plays a pivotal role in a wide array of diagnostic imaging procedures. For years, companies have been capitalizing on its high market demand. The industry, however, has started to witness a swift transition towards the emergence of generic Iopamidol. This change is fueled primarily by the attempt to reduce healthcare costs without compromising the quality or effectiveness of important diagnostic procedures. A clear example of this transitions impact can be observed in the substantial growth of several pharmaceutical companies that specialize in generic medical products. They have capitalized on the opening, driving competition and altering the market landscape dramatically. The transition has also had an echo effect on associated industries, leading to an increased sourcing of ingredients necessary to manufacture Iopamidol, further stimulating the economy.

2

Technological Advancements in Imaging Procedures:

Concurrently, advancements in technology have triggered a significant transition in how Iopamidol is utilized.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Other Healthcare industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Other Healthcare industry cascade into the Iopamidol market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Surging Demand for Diagnostic Imaging, and Technological Advancements

The proliferating adoption of Iopamidol in diagnostic imaging procedures sits at the center of its market growth. Acting as a contrast agent, Iopamidol aids in producing sharp images in various radiological examinations like Computed Tomography scans and X-rays. This facilitates the detection of abnormalities or diseases, thereby enhancing the efficiency and accuracy of diagnoses, which in turn also drives its demand
The advancements in the field of medical imaging technologies, and the subsequent emergence of innovative and upgraded diagnostic equipment, are also opening new avenues for the deployment of Iopamidol. The amplified focus on precision and patient safety has also led to improvements in contrast agents, with Iopamidol standing out due to its low toxicity and high vascular enhancement potential.
The steady increase in geriatric population, a segment more prone to chronic diseases and requiring frequent diagnostic tests, is also propelling the demand for Iopamidol. As medical practitioners prefer utilizing non-invasive diagnostic methods like CT scans, the use of Iopamidol becomes indispensable, owing to its effectiveness and safety profile

Restraint: Regulatory Constraints

In the healthcare sector, an important challenge rests with overcoming complex and dynamic regulatory protocols. Products such as Iopamidol, a non-ionic contrast medium, are subject to strict regulations by bodies like the FDA and EMA. Their stringent approval processes, especially for generic drugs, can slow down product distribution and limit market expansion. Additionally, any modifications to the product must be resubmitted for approval, potentially creating delays and additional costs in an already highly competitive market.

Challenge: High Production Costs

The production of non-ionic contrast mediums like Iopamidol is a capital-intensive process. The substantial investments required for research & development, clinical trials, production, and marketing limit the number of participants that can afford to enter and sustain in the market. Furthermore, the necessity of maintaining high production quality and efficacy, while keeping up with technological advancements, escalates the overall production costs.

Supply Chain Landscape

Raw Material Suppliers

BASF

Dow Chemicals

Intermediate Manufacturers

Bayer Healthcare

Siemens Healthineers

Product Manufacturers
Bracco Imaging / GE Healthcare
End User
Diagnostic Clinics / Hospitals / Research Institutes
Raw Material Suppliers

BASF

Dow Chemicals

Intermediate Manufacturers

Bayer Healthcare

Siemens Healthineers

Product Manufacturers

Bracco Imaging

GE Healthcare

End User

Diagnostic Clinics

Hospitals

Research Institutes

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Diagnostic Imaging
Healthcare
Bracco Diagnostics Inc.
Product Differentiation and Innovation
Vascular Procedures
Medical
Rapidscan Pharma Solutions Inc.
Portfolio Expansion and Technological Advancement
Neurological Examinations
Neurology
J.B. Chemicals and Pharmaceuticals Ltd.
Investment in Research and Development
Urological Imaging
Urology
Bayer AG
Strategic Partnerships and Collaborations

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Iopamidol market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Iopamidol in Myelography, Diagnostic Imaging and Cerebral Angiography

Myelography

Making full use of Iopamidol 300, Myelography is an essential application of this contrast agent. Iopamidol 300 aids in the visualization of the spinal cord, making this procedure crucial in diagnosing spinal disorders. Notably, due to its high contrast quality and lower toxicity, Iopamidol has become the gold standard in myelography.

Diagnostic Imaging

As a commonly used contrast medium, Iopamidol is widely applied in diagnostic imaging. Specifically, Iopamidol 300/370 is extensively utilized in this application for its capacity to enhance visibility during medical examinations including CT scans and MRI. Unique advantages include high tolerability, safety and minimal side effects. Top players in this sphere are Bracco Imaging and Bayer AG, where both continue to hold strong market positions due to their robust product portfolios and reliable services.

Cerebral Angiography

Iopamidol stands as a preferred choice in Cerebral Angiography. This form of medical imaging involves the use of Iopamidol 300/370 as a contrast agent to view blood vessels in and around the brain, outlining them with extreme precision. The most significant advantage is the isotonic nature of Iopamidol, which reduces patient discomfort during procedures. By focusing on enhancing patient comfort, leading firms such as GE Healthcare and Guerbet Group secure a significant position in this niche market.

Iopamidol vs. Substitutes:
Performance and Positioning Analysis

Iopamidol, a radiopaque contrast agent, is lauded for its lower side effects compared to alternatives such as Iodixanol. Its unique market positioning is in its potential for broader clinical application growth. These Alternatives specially Iomeprol has experienced a rapid growth as detailed in our latest report.

Iopamidol
  • Iohexol /
  • Iodixanol /
  • Iomeprol
    High contrast quality, widely tolerated and safe for patients
    Potential allergic reactions, may not be suitable for patients with renal impairment
    Proven safety profile, broad applicability in diagnostic imaging
    High cost, potential for allergic reactions

Iopamidol vs. Substitutes:
Performance and Positioning Analysis

Iopamidol

  • High contrast quality, widely tolerated and safe for patients
  • Potential allergic reactions, may not be suitable for patients with renal impairment

Iohexol / Iodixanol / Iomeprol

  • Proven safety profile, broad applicability in diagnostic imaging
  • High cost, potential for allergic reactions

Iopamidol, a radiopaque contrast agent, is lauded for its lower side effects compared to alternatives such as Iodixanol. Its unique market positioning is in its potential for broader clinical application growth. These Alternatives specially Iomeprol has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Iopamidol market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Other Healthcare ecosystem, we analyze Iopamidol across Hospitals, Diagnostic Imaging Centers, and Specialty Clinics Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Bayer AG, Bracco Imaging SpA, and Guerbet Group by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Intermediate Manufacturers, and Product Manufacturers. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Other Healthcare revenues to estimate the Iopamidol segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (BASF, Dow Chemicals), Intermediate Manufacturers (Bayer Healthcare, Siemens Healthineers), and Product Manufacturers. Our parallel substitute analysis examines Iohexol, Iodixanol, and Iomeprol, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Bayer AG, Bracco Imaging SpA, and Guerbet Group, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Iopamidol market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Iopamidol Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 669 million
Revenue Forecast in 2034USD 1.07 billion
Growth RateCAGR of 5.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024636 million
Growth OpportunityUSD 430 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024636 million USD
Market Size 2027742 million USD
Market Size 2029823 million USD
Market Size 2030867 million USD
Market Size 20341.07 billion USD
Market Size 20351.12 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredFormulation, Iodine concentration, Imaging Modality, End User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBayer AG, Bracco Imaging SpA, Guerbet Group, iMAX, J.B Chemicals and Pharmaceuticals Ltd, Jodas Expoim Pvt Ltd, GE Healthcare, Jiangsu Hengrui Medicine Co Ltd, Liebel-Flarsheim Company LLC, Nanopet Pharma GmbH, Liebel-Flarsheim Company LLC and Mallinckrodt Pharmaceuticals
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Iopamidol Market Size, Opportunities & Strategic Insights, by Formulation

4.1Intravenous
4.2Intra-arterial
4.3Intrathecal
4.4Intracavitary
Chapter 5

Iopamidol Market Size, Opportunities & Strategic Insights, by Iodine concentration

5.1300 mg
5.2370 mg
5.3200 mg
5.4250 mg
Chapter 6

Iopamidol Market Size, Opportunities & Strategic Insights, by Imaging Modality

6.1Computed Tomography
6.2Angiography
6.3Urography
6.4Myelography
6.5Arthrography
6.6Other Radiographic Procedures
Chapter 7

Iopamidol Market Size, Opportunities & Strategic Insights, by End User

7.1Hospitals
7.2Diagnostic Imaging Centers
7.3Specialty Clinics
Chapter 8

Iopamidol Market, by Region

8.1North America Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Iopamidol Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Bayer AG
9.2.2Bracco Imaging SpA
9.2.3Guerbet Group
9.2.4iMAX
9.2.5J.B Chemicals and Pharmaceuticals Ltd
9.2.6Jodas Expoim Pvt Ltd
9.2.7GE Healthcare
9.2.8Jiangsu Hengrui Medicine Co Ltd
9.2.9Liebel-Flarsheim Company LLC
9.2.10Nanopet Pharma GmbH
9.2.11Liebel-Flarsheim Company LLC
9.2.12Mallinckrodt Pharmaceuticals